Pfizer Inc today announced the results of a study that included 714 adult patients (ages 35-75 years), and found that 47 percent of smokers with a history of cardiovascular disease who took Champix® (Varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with just 13.9 percent of those given placebo. The findings were presented at the American College of Cardiology 58th Annual Scientific Session.
“This study demonstrates that Champix is effective in helping smokers with cardiovascular disease quit smoking. The safety profile of Champix in this study also resembles that of the pivotal studies. The results are encouraging because the participants were at greater risk for death given their advanced ages, durations of smoking and histories of cardiovascular disease,” said Dr. Nancy A. Rigotti, professor of medicine at Harvard Medical School, director of the Tobacco Research and Treatment Center at Massachusetts General Hospital, and lead study investigator.
Cigarette smoking is a well-established risk for cardiovascular disease. Studies have shown that quitting smoking reduces the risk of death by 36 percent for smokers who have coronary heart disease, a type of cardiovascular disease.
“Patients are always encouraged to quit smoking after experiencing a cardiac event, such as a heart attack or stroke, but many eventually start smoking again, putting themselves at serious risk for a second event,” said Dr. Robert A. Kloner, director of research at the Heart Institute of Good Samaritan Hospital and professor of medicine at the Keck School of Medicine at the University of Southern California in Los Angeles. “It’s important that every smoker, and particularly those with heart disease, work with a health care professional to develop a quit plan.”
Tobacco dependence is a chronic, relapsing, physical and psychological condition which makes quitting both necessary and difficult to achieve. By involving a physician, a smoker improves his or her chance to quit successfully through proper assessment, treatment and support.
Varenicline (Champix ®) is the first in a new class of treatment designed to help smokers reach their goal of quitting and staying quit. It is the first non-nicotine therapy specifically designed for smoking cessation by blocking nicotine from binding to the receptors in the brain that make tobacco so addictive.
About Pfizer Inc:
Founded in 1849, Pfizer is the world’s largest research-based pharmaceutical company taking new approaches to better health.
© 2000 - 2022 Al Bawaba (www.albawaba.com)